Supplement Market Regulatory Forecasts Vary From Stormy To Quiet
This article was originally published in The Tan Sheet
Executive Summary
The potential for legislation from Senators Durbin and Blumenthal d to tighten supplement industry regulation and for additional enforcement activity by FDA and DoJ as well as by state authorities are prominent on trade groups' radars for 2016.
You may also be interested in...
Trump Administration May Relax Supplement Industry Oversight, But Heighten Trade Concerns
Supplement industry trade associations see positives in working with President-elect Trump, including his focus on business, but they also express concern with the possibility of restrictive trade prospects.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.